Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Quoin Pharmaceuticals Q3 2026 Results: Net Loss of $4.87M, Loss Widens

Quoin Pharmaceuticals reported a net loss of $15.2 million for the nine months ended September 30, 2026, compared to $11.5 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through equity issuances, ending the period with $34.4 million in total current assets and $28.7 million in shareholders' equity.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.9-3.9

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: QNRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Quoin Pharmaceuticals Ltd.: key numbers

Share price
$3.56Close, Nov 16
Market cap
$250M
Shares outstanding
70.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Quoin Pharmaceuticals Ltd.

All →
5:05 PM ET 8-K
Other 8-K Filing

Quoin Pharmaceuticals Other 8-K Filing

Shareholders of Quoin Pharmaceuticals approved a proposal to amend beneficial ownership limitations for investors from previous private placements. The amendment allows investors to increase their ownership cap from 4.99% to up to 9.99% of outstanding ordinary shares upon written notice. This change applies to transactions consummated in October 2025 and August 2026 and aligns with both US and Israeli securities laws.

5:19 PM ET 8-K
Financial Results

Quoin Pharmaceuticals Financial Results

Quoin Pharmaceuticals reported third quarter 2026 financial results and provided a corporate update, including positive interim Phase 2/3 data for QRX003 in Netherton Syndrome. The company also highlighted a private placement financing of up to $50.0 million to fund the completion of QRX003 development. Topline data for the Netherton Syndrome study is expected in Q2 2027.

“The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth. Interim clinical results from our Phase 2/3 study of QRX003 in Netherton Syndrome demonstrated statistical significance for the primary and key secondary endpoints, representing what we believe is the first ever overall positive data set published for this disease.”

Dr. Michael Myers, Chief Executive Officer and Co-Founder

“Our priorities for the coming months are very clear. We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027.”

Dr. Michael Myers, Chief Executive Officer and Co-Founder
5:26 PM ET 8-K
Capital Raise

Quoin Pharmaceuticals Capital Raise

Quoin Pharmaceuticals entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell American Depositary Shares (ADSs) from time to time. Leerink Partners will act as the sales agent and receive a 3.0% commission on gross proceeds from any sales made under the program.

Counterparty
Leerink Partners LLC
6:35 AM ET 8-K
Clinical Trial Data

Quoin Pharmaceuticals Clinical Trial Data

Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.

Term
21 months
6:36 AM ET 8-K
Other 8-K Filing

Quoin Pharmaceuticals Other 8-K Filing

Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides 10 years of market exclusivity in Europe upon potential marketing authorization and follows similar regulatory milestones in the US and Japan. The company remains on track to initiate the first-ever formal clinical study for Peeling Skin Syndrome before the end of 2026.

Counterparty
European Medicines Agency
4:17 PM ET 8-K
Regulatory Approval

Quoin Pharmaceuticals Regulatory Approval

Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome. This is the first-ever Fast Track Designation granted for this rare genetic skin disease, which currently has no approved treatments. The company expects to initiate a Phase 2/3 clinical study for the indication in the second half of 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.